Form 4: Provectus Biopharmaceuticals CEO Acquires Convertible Promissory Note and Preferred Stock

CEO Edward Pershing acquired an 8% unsecured convertible promissory note and Series D-1 Convertible Preferred Stock in Provectus Biopharmaceuticals' 2022 Financing.

Summary

• Edward Pershing, CEO of Provectus Biopharmaceuticals, acquired an 8% unsecured convertible promissory note for $50,000 on June 20, 2024.
• This note can be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.
• Pershing also acquired 17,471 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 20, 2026, unless converted earlier.
• The note was issued pursuant to the Issuer's 2022 Financing.

Sentiment

Score: 5

Explanation: Neutral sentiment. The document simply reports a transaction. It doesn't inherently indicate positive or negative sentiment about the company's future.

Future Outlook

The Series D-1 Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

This filing reflects insider activity, which is closely monitored by investors for signals about management's confidence in the company's prospects. The acquisition of convertible securities can be seen as a form of investment in the company's future.

Key Dates